Barclays PLC Makes New $311,000 Investment in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Barclays PLC purchased a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,500 shares of the company’s stock, valued at approximately $311,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Stephens Inc. AR acquired a new position in Guardian Pharmacy Services during the 3rd quarter worth $189,000. Point72 DIFC Ltd acquired a new stake in shares of Guardian Pharmacy Services in the third quarter valued at $573,000. Royce & Associates LP acquired a new stake in shares of Guardian Pharmacy Services in the third quarter valued at $1,260,000. Foundry Partners LLC acquired a new stake in shares of Guardian Pharmacy Services in the third quarter valued at $1,680,000. Finally, Seven Grand Managers LLC acquired a new stake in shares of Guardian Pharmacy Services in the third quarter valued at $2,515,000.

Guardian Pharmacy Services Price Performance

Shares of NYSE GRDN opened at $20.53 on Monday. Guardian Pharmacy Services, Inc. has a 12 month low of $14.16 and a 12 month high of $25.74. The company’s fifty day moving average is $22.18.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($2.00) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($2.19). The company had revenue of $314.39 million during the quarter, compared to analysts’ expectations of $303.21 million. On average, research analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Insider Activity at Guardian Pharmacy Services

In other Guardian Pharmacy Services news, Director Steven D. Cosler purchased 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $21.22 per share, with a total value of $148,540.00. Following the completion of the transaction, the director now owns 17,713 shares of the company’s stock, valued at approximately $375,869.86. This represents a 65.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GRDN. Truist Financial upped their price objective on Guardian Pharmacy Services from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, November 15th. Raymond James began coverage on Guardian Pharmacy Services in a report on Monday, October 21st. They set an “outperform” rating and a $21.00 target price for the company. Finally, Stephens began coverage on Guardian Pharmacy Services in a report on Tuesday, October 22nd. They set an “overweight” rating and a $21.00 target price for the company.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.